Core Insights - BD's CFO Chris DelOrefice will leave the company on December 5, 2025, to take on a new role, with Vitor Roque appointed as interim CFO [1] - The company reported a preliminary revenue of approximately $5.9 billion for Q4 2025, reflecting an 8.3% year-over-year growth [3][5] - For the full fiscal year 2025, BD's revenue reached about $21.84 billion, marking an 8.2% increase compared to the previous year [7] - The company is transitioning from the "BD 2025" strategy to a new strategic plan called "New BD," focusing on sustainable growth and profitability [9][10] Financial Performance - Q4 2025 revenue was approximately $5.9 billion, with a year-over-year growth of 8.3% (7.0% at constant currency, 3.9% organic growth) [3][5] - Full-year revenue for 2025 was about $21.84 billion, showing an 8.2% increase (7.7% at constant currency, 2.9% organic growth) [7] - Key growth drivers included Interventional business, Advanced Patient Monitoring, and Medication Delivery Solutions, while Pharmaceutical Systems Vaccines and Biosciences faced challenges due to a slowdown in academic and government research projects [7] Strategic Transition - BD is set to unveil its "New BD" strategic plan and outlook for fiscal year 2026, indicating a shift from structural adjustments to a focus on continuous growth and profit quality [9] - The company has completed multiple integrations in surgical, drug delivery, diagnostics, and biosciences sectors, emphasizing high-growth areas like interventional therapy and digital monitoring [9] - The new strategy will prioritize profitability and cash flow quality over mere revenue expansion, as stated by CEO Tom Polen [9][10]